Article

Analysis of Clinical Features and Treatment Strategies in Advanced Lung Adenocarcinoma Patients With Acquired ALK Fusion After Resistance of EGFR-TKIs

2024-05-31

Abstract excerpt

<title>Abstract</title> <p>Background The mechanism of secondary drug resistance in advanced Non Small Cell Lung Cancer(NSCLC) patients with Epidermal Growth Factor Receptor (EGFR) gene sensitive mutation after EGFR-Tyrosine Kinase Inhibitors (TKIs) is complex. Acquired Anaplastic Lymphoma Kinase (ALK) fusion mutation is a rare type, and there are few reports on the clinical characteristics and treatment options...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: bf67206e-5a85-5764-97a8-70daa6da8135
DOI: 10.21203/rs.3.rs-4407880/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Analysis of Clinical Features and Treatment Strategies in Advanced Lung Adenocarcinoma Patients With Acquired ALK Fusion After Resistance of EGFR-TKIsDOI 10.21203/rs.3.rs-4407880/v1Read

Analysis of Acquired Fusion Mutations in EGFR-TKIs-Resistant Patients with Advanced Lung Cancer.Semantic proximity Read

The resistance mechanisms and treatment strategies for <i>EGFR</i>-mutant advanced non-small-cell lung cancerSemantic proximity Read

Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.Semantic proximity Read

[Molecular mechanisms of targeted drug resistance in lung cancer and its therapeutic strategy].Semantic proximity Read

Acquired resistance in oncogene-addicted non-small-cell lung cancer.Semantic proximity Read

Current Strategies for Treating NSCLC: From Biological Mechanisms to Clinical TreatmentSemantic proximity Read

[Advances in Double Mutations of EGFR and ALK Gene in Non-small Cell Lung Cancer].Semantic proximity Read

Efficacy and Acquired Resistance of EGFR-TKI Combined with Chemotherapy as First-Line Treatment for Chinese Patients with Advanced Non-Small Cell Lung Cancer in a Real-world SettingSemantic proximity Read

Oncogenic drivers in nonsmall cell lung cancer and resistance to epidermal growth factor receptor tyrosine kinase inhibitors.Semantic proximity Read

Drug resistance of targeted therapy for advanced non-small cell lung cancer harbored EGFR mutation: from mechanism analysis to clinical strategy.Semantic proximity Read

Emerging treatment for advanced lung cancer with EGFR mutation.Semantic proximity Read

[Targeted Therapy and Mechanism of Drug Resistance in Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor Gene Mutation].Semantic proximity Read